PTC Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

PTC Therapeutics şirketinin kazançları yıllık ortalama -15.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19% oranında artan oldu. Gelirler yıllık ortalama 25.4% oranında artan oldu.

Anahtar bilgiler

-15.8%

Kazanç büyüme oranı

-10.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	25.4%
Özkaynak getirisi	n/a
Net Marj	-53.3%
Sonraki Kazanç Güncellemesi	07 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

Gelir ve Gider Dağılımı

PTC Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:PTCT Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	900	-480	300
31 Mar 24	928	-579	319
31 Dec 23	938	-627	333
30 Sep 23	798	-642	349
30 Jun 23	819	-618	348
31 Mar 23	770	-571	340
31 Dec 22	699	-559	326
30 Sep 22	697	-531	320
30 Jun 22	618	-556	309
31 Mar 22	569	-522	298
31 Dec 21	539	-524	286
30 Sep 21	492	-455	274
30 Jun 21	472	-391	263
31 Mar 21	430	-454	247
31 Dec 20	381	-438	244
30 Sep 20	358	-441	233
30 Jun 20	311	-432	225
31 Mar 20	322	-292	220
31 Dec 19	307	-252	203
30 Sep 19	297	-222	188
30 Jun 19	279	-213	175
31 Mar 19	262	-181	159
31 Dec 18	265	-128	152
30 Sep 18	256	-78	139
30 Jun 18	245	-61	133
31 Mar 18	224	-69	129
31 Dec 17	194	-79	121
30 Sep 17	142	-107	108
30 Jun 17	123	-108	101
31 Mar 17	90	-130	95
31 Dec 16	83	-142	97
30 Sep 16	70	-166	99
30 Jun 16	57	-174	97
31 Mar 16	48	-174	90
31 Dec 15	37	-170	82
30 Sep 15	37	-147	74
30 Jun 15	29	-131	63
31 Mar 15	24	-118	55
31 Dec 14	25	-94	45
30 Sep 14	17	-84	34
30 Jun 14	32	-62	30
31 Mar 14	37	-51	28
31 Dec 13	35	-66	25

Kaliteli Kazançlar: PTCT şu anda kârlı değil.

Büyüyen Kar Marjı: PTCT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PTCT kârlı değildir ve zararlar son 5 yılda yılda 15.8% oranında artmıştır.

Büyüme Hızlandırma: PTCT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: PTCT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: PTCT 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

PTC Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Recent updates

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31